Literature DB >> 33485064

Crosstalk between PPARs and gut microbiota in NAFLD.

Liwei Wu1, Jingjing Li1, Jiao Feng2, Jie Ji2, Qiang Yu2, Yan Li2, Yuanyuan Zheng2, Weiqi Dai1, Jianye Wu3, Chuanyong Guo4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disorder in both China and worldwide. It ranges from simple steatosis and progresses over time to nonalcoholic steatohepatitis (NASH), advanced liver fibrosis, cirrhosis, or hepatocellular carcinoma(HCC). Furthermore, NAFLD and its complications impose a huge health burden to society. The microbiota is widely connected and plays an active role in human physiology and pathology, and it is a hidden 'organ' in determining the state of the host, in terms of homeostasis, or disease. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptorsuperfamily and can regulate multiple pathways involved in metabolism, and serve as effective targets forthe treatment of many types of metabolic syndromes, including NAFLD. The purpose of this review is to integrate related articles on gut microbiota, PPARs and NAFLD, and present a balanced overview on how the microbiota can possibly influence the development of NAFLD through PPARs.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Gut microbiota; NAFLD; PPAR

Mesh:

Substances:

Year:  2021        PMID: 33485064     DOI: 10.1016/j.biopha.2021.111255

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Effects of active, inactive, and derivatives of Akkermansia muciniphila on the expression of the endocannabinoid system and PPARs genes.

Authors:  Farinaz Ghaderi; Fattah Sotoodehnejadnematalahi; Zahra Hajebrahimi; Abolfazl Fateh; Seyed Davar Siadat
Journal:  Sci Rep       Date:  2022-06-15       Impact factor: 4.996

2.  Glycerol Monocaprylate Modulates Gut Microbiota and Increases Short-Chain Fatty Acids Production without Adverse Effects on Metabolism and Inflammation.

Authors:  Junhui Zhang; Fengqin Feng; Minjie Zhao
Journal:  Nutrients       Date:  2021-04-23       Impact factor: 5.717

3.  Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma.

Authors:  Boyuan Liu; Zewei Zhou; Yu Jin; Jinying Lu; Dongju Feng; Rui Peng; Hua Sun; Xiaoxin Mu; Changxian Li; Yun Chen
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

4.  Schisandrin B regulates macrophage polarization and alleviates liver fibrosis via activation of PPARγ.

Authors:  Qingshan Chen; Leilei Bao; Lei Lv; Fangyuan Xie; Xuwei Zhou; Hai Zhang; Guoqing Zhang
Journal:  Ann Transl Med       Date:  2021-10

Review 5.  PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.

Authors:  Naomi F Lange; Vanessa Graf; Cyrielle Caussy; Jean-François Dufour
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

Review 6.  The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

Authors:  Jingjing Li; Chuanyong Guo; Jianye Wu
Journal:  Drug Des Devel Ther       Date:  2021-06-18       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.